Big Pharma, facing dwindling millions from their Covid goo, is now chasing the next big Money-spinner, respiratory syncytial virus, or RSV. Two European drug companies, AstraZeneca and Sanofi, are seeking to have the Food and Drug Administration to approve an expensive new drug called nirsevimab for RSV for kids under age 1. The profits: $500-600 per child in the United States, or in the range of $2 billion annually if nirsevimab to “all infants.” But, there is a problem: “The companies’ own trials show far more deaths in infants who received nirsevimab than those who got either placebo or a competing older treatment. In the most important trial, of healthy near-full-term and full-term infants, three out of 994 infants given nirsevimab died within a year. None of the 496 infants who received a placebo shot died. In all, 12 infants treated with nirsevimab died in the trials, compared to four who were treated with an older antibody or a placebo. Even accounting for the fact that more infants received nirsevimab than placebo or the older antibody, infants given nirsevimab had a nearly 50 percent higher risk of death.”
This is like soldiers using a hand grenade that blows up as soon as the pin is pulled. But, that does not seem to worry the health authorities who look to rubber stamp this one too.
